Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Aug 21;26(16):8081.
doi: 10.3390/ijms26168081.

Metabolic Dysfunction-Associated Steatotic Liver Disease: A Silent Driver of Cardiovascular Risk and a New Target for Intervention

Giovanna Gallo  1 , Gabriele Nalli  1 , Francesco Baratta  2 , Giovambattista Desideri  3 , Carmine Savoia  1
Affiliations
Review

Metabolic Dysfunction-Associated Steatotic Liver Disease: A Silent Driver of Cardiovascular Risk and a New Target for Intervention

Giovanna Gallo et al. Int J Mol Sci. .

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) significantly increases the risk of steatohepatitis and cirrhosis and multiple extrahepatic complications, in particular, cardiometabolic disease, including type 2 diabetes, atherosclerotic cardiovascular disease (CVD), and heart failure, with a significant negative impact on health-related quality of life, becoming a substantial economic burden. Moreover, cardiovascular events represent the leading cause of death in MASLD patients. A timely diagnosis stratifies patient for their risk. It can facilitate early lifestyle changes or pharmacological management of dysmetabolic conditions, thereby slowing disease progression, lowering cardiovascular risk, and preventing CVD and cirrhosis. In this narrative review, we will discuss the current knowledge on MASLD and metabolic dysfunction-associated steatohepatitis (MASH) pathophysiology, emphasizing their systemic nature, the link to CVD, and available and emerging treatment strategies.

Keywords: GIP-1; GLP-1 agonists; MASH; MASLD; cardiometabolic risk; cardiovascular disease.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
MASLD pathophysiology and clinical outcome. FFA, free fatty acid accumulation.
Figure 2
Figure 2
MASLD and HFpEF interrelation. MASLD, metabolic-associated steatotic liver diseases); HFpEF, heart failure with preserved ejection fraction).
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Gan C., Yuan Y., Shen H., Gao J., Kong X., Che Z., Guo Y., Wang H., Dong E., Xiao J. Liver diseases: Epidemiology, causes, trends and predictions. Signal Transduct Target Ther. 2025;10:33. doi: 10.1038/s41392-024-02072-z. - DOI - PMC - PubMed
    1. Cusi K., Abdelmalek M.F., Apovian C.M., Balapattabi K., Bannuru R.R., Barb D., Bardsley J.K., Beverly E.A., Corbin K.D., ElSayed N.A., et al. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in People with Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association. Diabetes Care. 2025;48:1057–1082. doi: 10.2337/dci24-0094. - DOI - PubMed
    1. Ciardullo S., Perseghin G. Prevalence of elevated liver stiffness in patients with type 1 and type 2 diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract. 2022;190:109981. doi: 10.1016/j.diabres.2022.109981. - DOI - PubMed
    1. Stefan N., Cusi K. A global view of the interplay between nonalcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol. 2022;10:284–296. doi: 10.1016/S2213-8587(22)00003-1. - DOI - PubMed
    1. Younossi Z.M., Golabi P., Paik J.M., Henry A., Van Dongen C., Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review. Hepatology. 2023;77:1335–1347. doi: 10.1097/HEP.0000000000000004. - DOI - PMC - PubMed

LinkOut - more resources